Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 192 Products   52 Diseases   192 Products   3488 Trials   14990 News 


«12...345678910111213...202203»
  • ||||||||||  Early rapid progression after first-line CDK4/6 inhibitor (Exhibition Area) -  Feb 25, 2026 - Abstract #ESMOBC2026ESMO_BC_618;    
    Among 341 patients, At follow-up, 74 deaths occurred.23.8% experienced early rapid progression. In this single-center real-world study, Nearly one quarter of patients experienced early rapid progression after first-line CDK4/6 inhibitor
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Enrollment open, Phase classification, Enrollment change:  A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients (clinicaltrials.gov) -  Feb 18, 2026   
    P2/3,  N=240, Recruiting, 
    These findings suggest that immunotherapy may represent a potential treatment approach for high PD-L1 expression of METex14 NSCLC patients, warranting further investigation in larger cohorts. Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=138 --> 240
  • ||||||||||  oxaliplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
    Journal:  Alteration of tumor characteristics following neoadjuvant treatment in gastric adenocarcinoma: a case report. (Pubmed Central) -  Feb 16, 2026   
    Postoperative recovery was uneventful, and the patient was discharged in improved condition. Notably, postoperative pathological analysis revealed a neuroendocrine tumor, demonstrating an alteration in tumor histology after neoadjuvant therapy for gastric cancer (GC).
  • ||||||||||  cyclophosphamide / Generic mfg., Hengqu (hetrombopag) / Jiangsu Hengrui Pharma, cyclosporine / Generic mfg.
    Journal:  Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia. (Pubmed Central) -  Feb 16, 2026   
    Thrombopoietin receptor agonists combined with anti-thymocyte globulin (ATG) and cyclosporine (CsA) are the standard immunosuppressive therapy (IST) for severe/very severe aplastic anemia (SAA/VSAA)...Newly diagnosed SAA/VSAA patients received a combination treatment as follows: porcine ATG at 25 mg/kg/day from days 1 to 5, CsA at 3-5 mg/kg/day continuously, hetrombopag at 15 mg/day starting from day 1 and continued for 6 months, low-dose CTX at 20 mg/kg/day on days 29-30 and days 43-44...Infectious events occurred in 60.5% (26/43) of patients within the first 3 months of treatment, while no mortality observed during this period. Low-dose CTX combined with standard IST appears to improve the early response rate in SAA/VSAA patients with manageable toxicity.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) -  Feb 13, 2026   
    P2,  N=258, Recruiting, 
    Neoadjuvant chemoimmunotherapy shows high rates of pCR for ER-low BC, resembling triple-negative BC, with safety data indicating fewer severe complications than observed in pivotal trials. Active, not recruiting --> Recruiting | N=76 --> 258 | Trial completion date: Jul 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2027
  • ||||||||||  Review, Journal:  Cyclin-Dependent 4/6 Kinase Inhibitors for Treatment of HER2-Positive Breast Cancer: 2026 Update. (Pubmed Central) -  Feb 13, 2026   
    Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, abemaciclib, dalpiciclib) combined with endocrine therapy (ET) were a major advance in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) worldwide...However, clinical development of CDK4/6i in HER2+ MBC slowed, given the advent of highly effective tyrosine-kinase inhibitors (TKIs) (i.e., tucatinib) and antibody-drug conjugates (ADCs) (i.e., trastuzumab deruxtecan), which currently dominate the treatment armamentarium...Subsequently, the phase III PATINA trial (which included patients with 1L HR+HER2+ MBC, treated with palbociclib vs. placebo with maintenance ET+ H[P]) noted a striking PFS improvement of >15 months in the palbociclib arm, renewing interest in CDK4/6i-based treatments for HR+HER2+ MBC. Herein, we review the development of CDK4/6i in HER2+ BC, discussing current challenges and potential future directions.
  • ||||||||||  Retrospective data, Review, Journal:  Multi-Targeted TKIs in Patients with Advanced Ewing Sarcoma: A Systematic Review and Single-Arm Meta-Analysis. (Pubmed Central) -  Feb 13, 2026   
    The following TKIs were evaluated: cabozantinib, regorafenib, apatinib, anlotinib, sorafenib, lenvatinib, sunitinib, fruquintinib, and imatinib...Efficacy was consistently seen in both clinical trials and real-world studies. Nonetheless, there are important differences in study design and population that may limit our interpretation of efficacy and toxicity findings.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Journal:  CD24 overexpression confers resistance to Pyrotinib through inhibiting autophagy in patients with HER2-positive breast cancer. (Pubmed Central) -  Feb 12, 2026   
    Furthermore, CD24 knockdown reduced its expression level by promoting the ubiquitination modification of epidermal growth factor receptor (EGFR), and significantly inhibited its downstream AKT/mTOR signaling pathway. By interacting with EGFR and modulating the mTOR pathway, CD24 acted as a critical regulator of autophagic cell death, thereby enhancing the sensitivity of HER2+ BC cells and reversing Pyrotinib resistance.
  • ||||||||||  Review, Journal:  Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer. (Pubmed Central) -  Feb 9, 2026   
    TROP2 ADCs have shown antitumor responses with a manageable safety profile in patients with mNSCLC in several ongoing and completed trials. Additional studies are required to understand how these agents can be effectively integrated into the treatment paradigm for lung cancer, taking into consideration sequential use of multiple ADCs, resistance mechanisms, combination therapies, and use in special populations.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  SHR-A1811-I-102: A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) -  Feb 7, 2026   
    P1,  N=101, Completed, 
    TACE-TKI-Tisle offers balanced efficacy and safety, while TACE-TKI-Tori provides notable OS benefits, warranting further validation in prospective studies. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
  • ||||||||||  THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME:SYSTEMATIC REVIEW (ePoster Area) -  Feb 7, 2026 - Abstract #EBMT2026EBMT_1721;    
    This study is the first to demonstrate that hetrombopag significantly accelerates neutrophil and platelet engraftment in auto-HSCT patients compared to eltrombopag. Data regarding the efficacy and safety of PD-1 monoclonal antibodies used (such as sintilimab, nivolumab, camrelizumab, and tislelizumab) in both pediatric and adult patients with HLH were included...In pediatric patients (aged 3